These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 31553229

  • 1. High Expression of FGF5 Is an Independent Prognostic Factor for Poor Overall Survival and Relapse-Free Survival in Lung Adenocarcinoma.
    Zhao T, Qian K, Zhang Y.
    J Comput Biol; 2020 Jun; 27(6):948-957. PubMed ID: 31553229
    [Abstract] [Full Text] [Related]

  • 2. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
    Xu XL, Gong Y, Zhao DP.
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
    [Abstract] [Full Text] [Related]

  • 3. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
    Fu L, Wang H, Wei D, Wang B, Zhang C, Zhu T, Ma Z, Li Z, Wu Y, Yu G.
    PLoS One; 2020 Dec; 15(5):e0233283. PubMed ID: 32437446
    [Abstract] [Full Text] [Related]

  • 4. Differential MUC22 expression by epigenetic alterations in human lung squamous cell carcinoma and adenocarcinoma.
    Lin S, Tian C, Li J, Liu B, Ma T, Chen K, Gong W, Wang JM, Huang J.
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
    [Abstract] [Full Text] [Related]

  • 5. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
    Yang Y, Wang M, Liu B.
    J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
    [Abstract] [Full Text] [Related]

  • 6. System analysis of FHIT in LUAD and LUSC: The expression, prognosis, gene regulation network, and regulation targets.
    Situ Y, Gao R, Lei L, Deng L, Xu Q, Shao Z.
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [Abstract] [Full Text] [Related]

  • 7. UBE2D1 RNA Expression Was an Independent Unfavorable Prognostic Indicator in Lung Adenocarcinoma, but Not in Lung Squamous Cell Carcinoma.
    Hou L, Li Y, Wang Y, Xu D, Cui H, Xu X, Cong Y, Yu C.
    Dis Markers; 2018 Jun; 2018():4108919. PubMed ID: 30420903
    [Abstract] [Full Text] [Related]

  • 8. Increased GOLM1 Expression Independently Predicts Unfavorable Overall Survival and Recurrence-Free Survival in Lung Adenocarcinoma.
    Liu X, Chen L, Zhang T.
    Cancer Control; 2018 Jun; 25(1):1073274818778001. PubMed ID: 29843532
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
    Hou G, Lu Z, Bi Y, Deng J, Yang X.
    Med Oncol; 2022 Feb 12; 39(5):51. PubMed ID: 35150321
    [Abstract] [Full Text] [Related]

  • 11. Expression of SUMO1P3 Compared with SUMO1 is an Independent Predictor of Patient Outcome in Lung Adenocarcinoma.
    Su X, Wan Y, Xie L, Lin X, Zhao H, Ju X, Fang A.
    Med Sci Monit; 2019 Sep 06; 25():6691-6701. PubMed ID: 31489957
    [Abstract] [Full Text] [Related]

  • 12. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
    Gan BL, He RQ, Zhang Y, Wei DM, Hu XH, Chen G.
    Int J Oncol; 2018 Oct 06; 53(4):1557-1579. PubMed ID: 30066858
    [Abstract] [Full Text] [Related]

  • 13. High KRT8 Expression Independently Predicts Poor Prognosis for Lung Adenocarcinoma Patients.
    Xie L, Dang Y, Guo J, Sun X, Xie T, Zhang L, Yan Z, Amin H, Guo X.
    Genes (Basel); 2019 Jan 10; 10(1):. PubMed ID: 30634629
    [Abstract] [Full Text] [Related]

  • 14. High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.
    Zhou S, Wang P, Su X, Chen J, Chen H, Yang H, Fang A, Xie L, Yao Y, Yang J.
    PLoS One; 2017 Jan 10; 12(10):e0187356. PubMed ID: 29088286
    [Abstract] [Full Text] [Related]

  • 15. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
    Meng F, Zhang L, Ren Y, Ma Q.
    J Cell Physiol; 2019 Jul 10; 234(7):10918-10925. PubMed ID: 30549039
    [Abstract] [Full Text] [Related]

  • 16. Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer.
    Yu H, Pang Z, Li G, Gu T.
    J Clin Lab Anal; 2021 Feb 10; 35(2):e23588. PubMed ID: 32965722
    [Abstract] [Full Text] [Related]

  • 17. PLEK2 Gene Upregulation Might Independently Predict Shorter Progression-Free Survival in Lung Adenocarcinoma.
    Zhang W, Li T, Hu B, Li H.
    Technol Cancer Res Treat; 2020 Feb 10; 19():1533033820957030. PubMed ID: 33084541
    [Abstract] [Full Text] [Related]

  • 18. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N, Li Y, Zheng P, Zhan X.
    Front Endocrinol (Lausanne); 2021 Feb 10; 12():755805. PubMed ID: 34745015
    [Abstract] [Full Text] [Related]

  • 19. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
    Li Y, Sun N, Lu Z, Sun S, Huang J, Chen Z, He J.
    Cancer Lett; 2017 May 01; 393():40-51. PubMed ID: 28223168
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.